New drug classification: treatment with biological products class 1 new drug (2017 l04439 clinical certificate no. :)

Indications: for detoxification of malignant tumor chemotherapy

Project progress: the upcoming phase I clinical trials

2 patents authorized patent status: :

1, the recombinant carboxypeptidase G2 expression vector method and preparation of recombinant carboxypeptidase G2, patent number: ZL 200910103526.1;

2, a recombinant carboxypeptidase G2 drug combination, patent number: ZL 201110363684.8

Project introduction: recombinant carboxypeptidase G2 can degradation of MTX, therefore in clinic as an antidote to save patients with acute renal failure caused by high-dose MTX chemotherapy. Preclinical animal studies have shown that recombinant carboxypeptidase G2 and mistake the joint application of high-dose MTX chemotherapy, can cause no animal poisoning cases maximizes increase dosage of MTX and its anti-tumor activity, which in the expansion of high-dose MTX treatment of malignant tumor, safety, applicable scope and improve the effect of treatment is a positive signal, is expected to develop a cheap safe and effective for malignant tumor treatment. At present in our country were seen in malignant tumor has more than 4 million, in a large patient population accounts for the vast majority of low-income people to this kind of relatively cheap strong just need effective treatments. My company's restructuring carboxypeptidase G2, only in new cases of the market, sales is expected to reach at least 1 billion yuan/year, potential market more than 5 billion yuan/year.